Your directors have pleasure in presenting the Directors’ Report and the Audited Statement of Accounts
of the Company for the Financial Year ended 31st March 2025.

1. FINANCIAL SUMMARY/HIGHLIGHTS:

The performance of the Company during the year has been as under:

(Rs. In Lakhs)

2. REVIEW OF OPERATIONS:

The total revenue of the Company for the financial year on a standalone basis under review was
?3,694.65 lakhs as against total revenue of ?4,327.00 lakhs for the previous financial year. The
Company recorded a net profit of ?29.57 lakhs for the financial year 2024-25 as against the net profit
of ?41.94 lakhs for the previous year.

The total revenue of the Company for the financial year on a consolidated basis under review was
?4,525.91 lakhs as against total revenue of ?4,493.38 lakhs for the previous financial year. The
Company recorded a net profit of ?33.62 lakhs for the financial year 2024-25 as against the net profit
of ?47.24 lakhs for the previous year.

The marginal increase in consolidated revenue is driven primarily by improved operational efficiencies
and performance of the subsidiary entities. However, a slight dip in net profit reflects higher expenses
and taxation during the year. The Company remains focused on strengthening its market position, cost
management, and strategic initiatives for sustainable growth in the coming years.

3. CONSOLIDATED FINANCIAL STATEMENTS

In accordance with Companies Act, 2013 (“the Act”) and Ind AS 110 - Consolidated Financial
Statements read with Ind AS 28

The audited consolidated financial statements form part of the Annual Report.

In terms of provision to sub section (3) of Section 129 of the Act, the salient features of the financial

statements of the Subsidiaries and Associates are set out in the prescribed Form AOC-1, which forms
a part of the Annual Report. In accordance with Section 136 of the Act, the audited financial statements,
including the consolidated financial statements of the Company and audited accounts of the
subsidiaries are available at the Company’s website: https://www.Concorddrugs.com/investors/.

The documents will also be available for inspection during business hours at the registered office of the
Company

4. DIVIDEND:

Your directors have decided not to recommend any dividend for the year 2024-25.

5. BUSINESS UPDATE AND STATE OF COMPANY’S AFFAIRS:

The information on Company’s affairs and related aspects is provided under Management Discussion
and Analysis report, which has been prepared, inter-alia, in compliance with Regulation 34 of SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 and forms part of this Report.

6. RESERVES:

Pursuant to the provisions of Section 134(3)(j) of the Companies Act, 2013, the Company has not
proposed to transfer any amount to the general reserves account during the financial year under review.
The closing balance of reserves, including retained earnings, of the Company as at March 31, 2025,
stands at ?2,411.37 Lakhs.

7. CHANGE IN THE NATURE OF THE BUSINESS, IF ANY:

During the period under review and the date of Board's Report there was no change in the nature of
Business.

8. MATERIAL CHANGES & COMMITMENT AFFECTING THE FINANCIAL POSITION OF THE
COMPANY:

There are no major material changes and commitments affecting the financial position of the Company
after the end of the financial year and up to date of this report.

9. REVISION OF FINANCIAL STATEMENTS:

There was no revision of the financial statements for the year under review.

10. SHARE CAPITAL:

The authorized share capital of the Company stands at Rs.11,00,00,000/- divided into 1,10,00,000
equity shares of Rs. 10/- each.

The paid-up share capital of the Company stands at Rs. 10,00,00,000/- divided into 1,00,00,000/- equity
shares of Rs. 10/- each.

Company has taken approval from shareholders for increase of Authorized capital from 11,00,00,000
to 15,50,00,000/- on EGM held on 31.07.2025

11. UNPAID / UNCLAIMED DIVIDEND:

There is no unpaid or unclaimed dividend with the company till date.

12. INVESTOR EDUCTION AND PROTECTION FUND (IEPF):

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund Authority
(Accounting, Audit, Transfer and Refund) Rules, 2016 (“IEPF Rules”) read with the relevant circulars
and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven

years from the due date is required to be transferred to the Investor Education and Protection Fund
(“IEPF”), constituted by the Central Government.

During the Year, no amount of dividend/ was unpaid or unclaimed for a period of seven years and
therefore no amount/shares is required to be transferred to Investor Education and Provident Fund
under the Section 125 (1) and Section 125 (2) of the Act.

13. APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS /CEO/ CFO
AND KEY MANANGERIAL PERSONNEL:

The Board of Directors wishes to inform that there were no changes in the composition of the Board
during the financial year. No appointments or resignations of Directors took place during the year under
review.

14. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS:

The Company has received declarations from all the Independent Directors of the Company to the effect
that they are meeting the criteria of independence as provided in Sub-Section (6) of Section 149 of the
Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015.

The Independent Directors have also confirmed that they have complied with the Company’s Code of
Conduct.

In terms of Regulations 25(8) of the Listing Regulations, the Independent Directors have confirmed that
they are not aware of any circumstance or situation, which exists or may be reasonably anticipated, that
could impair or impact their ability to discharge their duties with an objective independent judgement
and without any external influence.

During the year, Independent Directors of the Company had no pecuniary relationship or transactions
with the Company, other than sitting fees, commission and reimbursement of expenses incurred by
them for the purpose of attending meetings of the Board of Directors and Committee(s).

In the opinion of the Board, all the Independent Directors possess requisite qualifications, experience,
expertise and hold high standards of integrity for the purpose of Rule 8(5)(iiia) of the Companies
(Accounts) Rules, 2014.

15. BOARD MEETINGS:

The Board of Directors duly met Six (6) times during the financial year from 1st April 2024 to 31st March
2025. The dates on which the meetings were held are given in elsewhere in the same report.

16. MECHANISM FOR EVALUATION OF THE BOARD:

The Board of Directors has carried out an annual evaluation of its own performance, board committees,
and individual directors pursuant to the provisions of the Act and SEBI Listing Regulations.

The performance of the board was evaluated by the board after seeking inputs from all the directors on
the basis of criteria such as the board composition and structure, effectiveness of board processes,
information and functioning, etc.

The performance of the committees was evaluated by the board after seeking inputs from the committee
members on the basis of criteria such as the composition of committees, effectiveness of committee
meetings, etc.

The above criteria are based on the Guidance Note on Board Evaluation issued by the Securities and
Exchange Board of India on January 5, 2017.

In a separate meeting of independent directors, performance of independent directors, the board as a
whole and the Chairman of the Company was evaluated, taking into account the views of executive
directors and non-executive directors.

The Board reviewed the performance of individual directors on the basis of criteria such as the
contribution of the individual director to the board and committee meetings like preparedness on the
issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc.

In the board meeting that followed the meeting of the independent directors and meeting of Nomination
and Remuneration Committee, the performance of the board, its committees, and individual directors
was also discussed.

Performance evaluation of independent directors was done by the entire board, excluding the
independent director being evaluated.

17. STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF
REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE 5(2) & (3) OF
THE COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:

A table containing the particulars in accordance with the provisions of Section 197(12) of the Act, read
with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules,
2014 is appended as Annexure 1 to this Report.

A statement showing the names of the top ten employees in terms of remuneration drawn and the name
of every employee is annexed to this Annual report as Annexure 2.

During the year, NONE of the employees is drawing a remuneration of Rs.1,02,00,000/- and above per
annum or Rs. 8,50,000/- and above in aggregate per month, the limits specified under the Section
197(12) of the Companies Act,2013 read with Rules 5(2) and 5(3) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014.

18. RATIO OF REMUNERATION TO EACH DIRECTOR:

Under section 197(12) of the Companies Act, 2013, and Rule 5(1) (2) & (3) of the Companies
(Appointment & Remuneration) Rules, 2014 read with Schedule V of the Companies Act, 2013 the ratio
of remuneration of Mr. S. Nagi Reddy, Chairman and Managing Director, Mr. S. Koni Reddy, Whole
time director and CFO and Mr. S. Manoj Reddy, Whole time director of the Company to the median
remuneration of the employees is given as disclosure respectively in this report else where.

19. DIRECTORS’ RESPONSIBILITY STATEMENT:

Pursuant to the requirement of Section 134(3)(c) and 134(5) of the Companies Act, 2013 and on the
basis of explanation given by the executives of the Company and subject to disclosures in the Annual
Accounts of the Company from time to time, we state as under:

i. That in the preparation of the annual accounts, the applicable accounting standards have been
followed along with proper explanation relating to material departures;

ii. That the Directors have selected such accounting policies and applied them consistently and
made judgment and estimates that are reasonable and prudent so as to give a true and fair
view of the state of affairs of the Company at the end of the financial year and of the profit or
loss of the Company for that period;

iii. That the Directors have taken proper and sufficient care for the maintenance of adequate
accounting records in accordance with the provisions of this Act for safeguarding the assets of
the Company and for preventing and detecting fraud and other irregularities;

iv. That the Directors have prepared the annual accounts on a going concern basis:

v. That the Directors have lain down internal financial controls to be followed by the Company and
that such internal financial controls are adequate and are operating effectively; and

vi. That the Directors have devised proper systems to ensure compliance with the provisions of all
applicable laws and that such systems are adequate and operating effectively.

20. INTERNAL AUDIT AND FINANCIAL CONTROLS:

The Company has adequate internal controls consistent with the nature of business and size of the
operations, to effectively provide for safety of its assets, reliability of financial transactions with adequate

checks and balances, adherence to applicable statues, accounting policies, approval procedures and
to ensure optimum use of available resources. These systems are reviewed and improved on a regular
basis. It has a comprehensive budgetary control system to monitor revenue and expenditure against
approved budget on an ongoing basis.

During the period under review, there is no material or serious observations have been noticed for
inefficiency or inadequacy of such controls.

Further, details of internal financial control and its adequacy are included in the Management Discussion
and Analysis Report which is appended as Annexure 6 and forms part of this Report.

21. DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB SECTION (12) OF
SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL
GOVERNMENT:

There have been no frauds reported by the auditor’s u/s 143(12).

22. CEO/ CFO CERTIFICATION:

The Managing Director and Whole-time director and CFO certification of the financial statements for
the year 2024-25 is annexed in this Annual Report.

23. INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE
SUBSIDIARIES / ASSOCIATES/ JOINT VENTURES:

The company has one subsidiary, Proton Remedies Private Limited.

As per the provisions of Section 129 of the Companies Act, 2013 read with Companies (Accounts)
Rules, 2014, a separate statement containing the salient features of the financial statements of the
associate company is prepared in Form AOC-1 and is attached as Annexure 3 and forms part of this
report.

24. DETAILS OF DEPOSITS

Since the Company has not accepted any deposits during the Financial Year ended March 31,2025,
there has been no non-compliance with the requirements of the Act.

Pursuant to the Ministry of Corporate Affairs (MCA) notification dated 22nd January 2019 amending the
Companies (Acceptance of Deposits) Rules, 2014, the Company is required to file with the Registrar of
Companies (ROC) requisite returns in Form DPT-3 for outstanding receipt of money/loan by the
Company, which is not considered as deposits.

The Company complied with this requirement within the prescribed timelines.

25. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

The Company has not given any loan, guarantees or made any investments exceeding the limits under
the provisions as prescribed in Section 186 of the Companies Act, 2013.

26. RELATED PARTY TRANSACTIONS:

Our Company has formulated a policy on related party transactions which is also available on
Company’s website at www.concorddrugs.in. This policy deals with the review and approval of related
party transactions.

All related party transactions that were entered into during the financial year were on arm’s length basis
and were in the ordinary course of business. There were no material significant related party
transactions made by the Company with the Promoters, Directors, Key Managerial Personnel or the
Senior Management which may have a potential conflict with the interest of the Company at large.
Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the
Companies Act, 2013 in the prescribed Form AOC-2 is appended as Annexure 4 which forms part of

this Report.

All related party transactions were placed before the Audit Committee/Board for approval. Prior approval
of the Audit Committee was obtained for the transactions which are foreseen and are in repetitive in
nature. Members may refer to the financial statement which sets out related party disclosures pursuant
to IND AS- 24.

27. DISCLOSURE OF PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY,
TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

The particulars as prescribed under Section 134(3) (m) of the Companies Act, 2013, are provided
hereunder:

A. Conservation of Energy:

Your Company’s operations are not energy intensive. Adequate measures have been taken to
conserve energy wherever possible by using energy efficient computers and purchase of
energy efficient equipment.

B. Research & Development and Technology Absorption:

Research and Development (R&D): NIL
Technology absorption, adoption and innovation: NIL

C. Foreign Exchange Earnings and Out Go:

Foreign Exchange Earnings: NIL
Foreign Exchange Outgo: NIL

28. COMMITTEES:

i. AUDIT COMMITTEE

During the year, the Audit Committee is in line with the provisions of Regulation 18(1) of SEBI (LODR)
Regulations read with Section 177 of the Companies Act, 2013 are included in the Corporate
Governance report, which forms part of this report.

ii. NOMINATION AND REMUNERATION COMMITTEE

During the year, the Nomination and Remuneration Committee is in line with the provisions of
Regulation 19(1) of SEBI (LODR) Regulations read with Section 178 of the Companies Act, 2013 are
included in the Corporate Governance report, which forms part of this report.

iii. STAKEHOLDERS RELATIONSHIP COMMITTEE

During the year, the Stakeholders Relationship Committee is in line with the provisions of Regulation
20 of SEBI (LODR) Regulations read with Section 178 of the Companies Act, 2013 are included in the
Corporate Governance report, which forms part of this report.

29. CORPORATE SOCIAL RESPONSIBILITY (CSR, COMPOSITION OF CSR COMMITTEE AND
CONTENTS OF CSR POLICY):

Since your Company does not have net worth of Rs. 500 Crores or more or turnover of Rs. 1000 Crores
or more or a net profit of Rs. 5 Crores or more during the financial year, section 135 of the Companies
Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need
not adopt any Corporate Social Responsibility Policy.

30. VIGIL MECHANISM/WHISTLE BLOWER POLICY:

In pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013 read with Regulation
22 of SEBI (LODR) Regulations, 2015, a vigil Mechanism for Directors and employees to report genuine
concerns has been established. It also provides for necessary safeguards for protection against
victimization for whistle blowing in good faith.

Vigil Mechanism Policy has been established by the Company for directors and employees to report
genuine concerns pursuant to the provisions of section 177(9) & (10) of the Companies Act, 2013. The
same has been placed on the website of the Company.

31. SIGNIFICANT & MATERIAL ORDERS PASSED BY COURTS / REGULATORS / TRIBUNALS:

There are no significant and material orders passed by the regulators /courts that would impact the
going concern status of the Company and its future operations.

32. AUDITORS:

i. Statutory Auditors

Pursuant to the provisions of Section 139 of the Act and the rules framed thereafter,
M/s. Pundari Kashyam & Associates., Chartered Accountants, Hyderabad were appointed as statutory
auditors of the Company from the conclusion of the 26th Annual General Meeting (AGM) of the
Company held on 30.09.2021 till the conclusion of the 31st AGM to be held in the year 2026.

The notes on accounts referred to in the auditors’ report are self-explanatory and therefore don’t call for
any further comments by the Board of directors.

There are no qualifications or adverse remarks in the Auditors’ Report which require any clarification or
explanation.

Statutory Auditors Report

The Board has duly reviewed the Statutory Auditor’s Report on the Accounts for the year ended March
31,2025 and has noted that the same does not have any reservation, qualification or adverse remarks.
However, the Board decided to further strengthen the existing system and procedures to meet all kinds
of challenges and growth in the coming years.

ii. Secretarial Auditor

Pursuant to the provisions of Section 134(3) (f) & Section 204 of the Companies Act, 2013, the Board
has appointed M/s. PSK and, Practicing Company Secretaries has undertaken Secretarial Audit of the
Company for financial year ending 31.03.2025. The report of the Secretarial Auditor is enclosed
herewith vide Annexure 5 of this Report.

Secretarial Audit Report:

The Board has duly reviewed the Secretarial Audit Report for the year ended March 31, 2025 on the
Compliances according to the provisions of Section 204 of the Companies Act, 2013.

There are no qualifications or adverse remarks in the Secretarial Auditors’ Report which require any
clarification or explanation.

Annual Secretarial Compliance Report:

SEBI vide its Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 read with Regulation 24(A)
of the Listing Regulations, directed listed entities to conduct Annual Secretarial compliance audit from
a Practicing Company Secretary of all applicable SEBI Regulations and circulars/guidelines issued
thereunder. Further, Secretarial Compliance Report dated 29.05.202, was given by Practicing Company
Secretary which was submitted to Stock Exchange within 60 days of the end of the financial year.

iii. Cost Auditor

The Company is in due compliance with the Companies (Cost Records and Audit) Rules, 2014. M/s.
KJU & Associates, Cost Accountants are the Cost Auditors of the Company for the FY 2024-25.

iv. Internal Auditor

Pursuant to provisions of Section 138 read with Rule 13 of the Companies (Accounts) Rules, 2014 and
Section 179 read with Rule 8(4) of the Companies (Meetings of Board and its Powers) Rules, 2014;
M/s. Nazeerudeen & Co., Chartered Accountants were appointed as Internal Auditors of the Company

for the Financial Year 2024-25.

Deviations are reviewed periodically and due compliance ensured. Summary of Significant Audit
Observations along with recommendations and its implementations are reviewed by the Audit
Committee and concerns, if any, are reported to Board.

33. SECRETARIAL STANDARDS:

The Company is in compliance with the applicable secretarial standards.

34. DECLARATION BY THE COMPANY:

The Company has issued a certificate to its Directors, confirming that it has not made any default under
Section 164(2) of the Companies Act, 2013, as on March 31,2025.

35. ANNUAL RETURN:

As required pursuant to Section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies
(Management and Administration) Rules, 2014, an annual return is disclosed on the website
www.concorddrugs.in.

36. DISCLOSURE ABOUT COST AUDIT:

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section
148(1) of the Act, are not applicable for the business activities carried out by the Company.

37. MANAGEMENT DISCUSSIONS AND ANALYSIS REPORT:

The Management Discussion and Analysis Report, pursuant to the SEBI (LODR) Regulation provides
an overview of the affairs of the Company, its legal status and autonomy, business environment, mission
& objectives, sectoral and operational performance, strengths, opportunities, constraints, strategy and
risks and concerns, as well as human resource and internal control systems is appended as Annexure
6 for information of the Members.

38. FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS:

Independent Directors are familiarized about the Company’s operations and businesses. Interaction
with the Business heads and key executives of the Company is also facilitated. Detailed presentations
on important policies of the Company are also made to the directors. Direct meetings with the Chairman
are further facilitated to familiarize the incumbent Director about the Company/its businesses and the
group practices.

39. POLICY ON DIRECTOR’S APPOINTMENT AND REMUNERATION AND OTHER DETAILS:

The assessment and appointment of Members to the Board is based on a combination of criterion that
includes ethics, personal and professional stature, domain expertise, gender diversity and specific
qualification required for the position. The potential Board Member is also assessed on the basis of
independence criteria defined in Section 149(6) of the Companies Act, 2013 and Regulation 27 of SEBI
(LODR) Regulations, 2015.

In accordance with Section 178(3) of the Companies Act, 2013 and Regulation 19(4) of SEBI (LODR)
Regulations, 2015, on the recommendations of the Nomination and Remuneration Committee, the
Board adopted a remuneration policy for Directors, Key Management Personnel (KMPs) and Senior
Management. The Policy is attached a part of Corporate Governance Report.

We affirm that the remuneration paid to the Directors is as per the terms laid down in the Nomination
and Remuneration Policy of the Company.

40. INSURANCE:

The properties and assets of your Company are adequately insured.

41. CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION:

The Company has implemented all of its major stipulations as applicable to the Company. As stipulated
under Regulation 34 read with schedule V of SEBI (LODR) Regulations, 2015, a report on Corporate
Governance duly audited is appended as Annexure 7 for information of the Members.

The Certificate(s) issued by M/s PSK & Associates, Practicing Company Secretaries, pertaining to
compliance of ‘Corporate Governance’ conditions as applicable to the Company is annexed to
Corporate Governance Report.

42. NON-EXECUTIVE DIRECTORS’ COMPENSATION AND DISCLOSURES:

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with
the Company which in the Judgment of the Board may affect the independence of the Directors.

No compensation was paid to the Independent and Non-Executive Directors.

43. COMPANY’S POLICY ON DIRECTORS’ APPOINTMENT AND REMUNERATION INCLUDING
CRITERIA FOR DETERMINING QUALIFICATIONS, POSITIVE ATTRIBUTES, INDEPENDENCE OF
A DIRECTOR AND OTHER MATTERS PROVIDED UNDER SUB-SECTION (3) OF SECTION 178:

The assessment and appointment of Members to the Board is based on a combination of criterion that
includes ethics, personal and professional stature, domain expertise, gender diversity and specific
qualification required for the position. The potential Board Member is also assessed on the basis of
independence criteria defined in Section 149(6) of the Companies Act, 2013 and Regulation 27 of SEBI
(LODR) Regulations, 2015. In accordance with Section 178(3) of the Companies Act, 2013 and
Regulation 19(4) of SEBI (LODR) Regulations, 2015, on the recommendations of the Nomination and
Remuneration Committee, the Board adopted a remuneration policy for Directors, Key Management
Personnel (KMPs) and Senior Management. The Policy is attached a part of Corporate Governance
Report. We affirm that the remuneration paid to the Directors is as per the terms laid down in the
Nomination and Remuneration Policy of the Company.

44. CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:

The Board of Directors has adopted the Insider Trading Policy in accordance with the requirements of
the SEBI (Prohibition of Insider Trading) Regulation, 2015 and the applicable Securities laws. The
Insider Trading Policy of the Company lays down guidelines and procedures to be followed, and
disclosures to be made while dealing with shares of the Company, as well as the consequences of
violation. The policy has been formulated to regulate, monitor and ensure reporting of deals by
employees and to maintain the highest ethical standards of dealing in Company securities. The Insider
Trading Policy of the Company covering code of practices and procedures for fair disclosure of
unpublished price sensitive information and code of conduct for the prevention of insider trading, is
available on our website.

45. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE
(PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The
Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal
Complaint Committee (ICC) has been set up to redress complaints received regarding sexual
harassment. No Complaints were pending at the beginning of the year or received during the year.

46. INDUSTRY BASED DISCLOSURES AS MANDATED BY THE RESPECTIVE LAWS GOVERNING

THE COMPANY:

The Company is not a NBFC, Housing Companies etc., and hence Industry based disclosures is not
required.

47. FAILURE TO IMPLEMENT CORPORATE ACTIONS:

During the year under review, no corporate actions were done by the Company which were failed to be
implemented.

48. DETAILS OF APPLICATION MADE OR PROCEEDING PENDING UNDER INSOLVENCY AND
BANKRUPTCY CODE, 2016:

During the year under review, there were no applications made or proceedings pending in the name of
the Company under Insolvency and Bankruptcy Code, 2016.

49. DETAILS OF DIFFERENCE BETWEEN VALUATION AMOUNT ON ONE TIME SETTLEMENT AND
VALUATION WHILE AVAILING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS:

During the year under review, there has been no one time settlement of loans taken from banks and
financial institutions.

50. POLICIES:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the
formulation of certain policies for all listed companies. All the policies are available on our website
www.concorddrugs.in.

51. EVENT BASED DISCLOSURES:

During the year under review, the Company has not taken up any of the following activities except as
mentioned:

Issue of sweat equity share: NA

Issue of shares with differential rights: NA

Issue of shares under employee’s stock option scheme: NA

Disclosure on purchase by Company or giving of loans by it for purchase of its shares: NA
Buy back shares: NA
Disclosure about revision: NA

Preferential Allotment of Shares:The Company has conducted an Extra-Ordinary General Meeting
(EGM) on 31.07.2025 for approving and issuance of equity shares on preferential basis (i) 31,75,000
(Thirty-One Lakhs Seventy-Five Thousand Only) equity shares at a price of ?36.30/- (Rupees Thirty-
Six and Thirty Paise Only) each (including premium of ?26.30/-), and (ii) 20,25,000 (Twenty Lakhs
Twenty-Five Thousand Only) convertible warrants, each convertible into one fully paid-up equity share
of face value ?10/- at a price of ?36.30/- (including premium of ?26.30/-), to Promoters/Promoter Group
and certain identified Non-Promoter persons (“Proposed Allottees”). The Company has filed the
necessary applications and is awaiting in-principle approval from the Stock Exchange. As on the date
of this report, no allotment of shares or warrants has been made.

52. DISCLOSURE OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

The Internal Financial Controls with reference to financial statements as designed and implemented by
the Company are adequate. The Company maintains appropriate system of internal control, including
monitoring procedures, to ensure that all assets are safeguarded against loss from unauthorized use
or disposition. Company policies, guidelines and procedures provide for adequate checks and balances,
and are meant to ensure that all transactions are authorized, recorded and reported correctly.

During the period under review, there is no material or serious observations have been noticed for

inefficiency or inadequacy of such controls. Further, details of internal financial control and its adequacy
are included in the Management Discussion and Analysis Report which is appended as Annexure 6
and forms part of this Report.

53. CONSOLIDATED FINANCIAL STATEMENTS:

The company does not have any subsidiary at the end of financial year under the review. However, it
is having an associate company and in compliance with the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (hereinafter referred to as the ‘Listing Regulations’) and Section 129
of the Companies Act, 2013, the Consolidated Financial Statements have been prepared by the
Company in accordance with the applicable provisions of the Companies Act, 2013 and the applicable
Indian Accounting Standards (Ind AS) and forms part of this Annual Report.

54. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES,
JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR:

During the year under review Proton Remedies Private Limited is its subsidiary as on 31.03.2025 and
no Company has become or ceased to become its joint ventures or associate Company.

55. PUBLIC DEPOSITS:

Your Company has not accepted any deposits falling within the meaning of Sec.73, 74 & 76 of the
Companies Act, 2013 read with the Rule 8(v) of Companies (Accounts) Rules 2014, during the financial
year under review.

56. CREDIT & GUARANTEE FACILITIES:

The Company has not availed credit and guarantee facilities.

57. RISK MANAGEMENT POLICY:

Business Risk Evaluation and Management is an ongoing process within the Organization. The
Company has a robust risk management framework to identify, monitor and minimize risks and also to
identify business opportunities. As a process, the risks associated with the business are identified and
prioritized based on severity, likelihood and effectiveness of current detection. Such risks are reviewed
by the senior management on a periodical basis. Risk Management Committee of the Board of Directors
of your Company assists the Board in

overseeing and approving the Company’s enterprise-wide risk management framework; and
overseeing that all the risks that the organization faces such as strategic, financial, credit, market,
liquidity, security, property, IT, legal, regulatory, reputational, other risks have been identified and
assessed, and there is an adequate risk management infrastructure in place capable of addressing
those risks. The development and implementation of risk management policy has been covered in the
Management Discussion and Analysis, which forms part of this Report.

58. ENVIRONMENTS AND HUMAN RESOURCE DEVELOPMENT:

Your Company always believes in keeping the environment pollution free and is fully committed to its
social responsibility. The Company has been taking upmost care in complying with all pollution control
measures from time to time strictly as per the directions of the Government. We would like to place on
record our appreciation for the efforts made by the management and the keen interest shown by the
Employees of your Company in this regard.

59. ADJUDICATION ORDER AND SHOW CAUSE NOTICES:

SEBI vide its order dated August 11,2023 has imposed a penalty on the Company, Directors and other
KMPs for alleged violation of SEBI Regulations and in continuation to that SEBI has initiated recovery
and issued recovery certificate completion dated 19.08.2024 to the Mr. Nagi Reddy Seelam and Mr.

Koni Reddy Seelam. Further, Company has received Notices from Ministry of Corporate Affairs, Cost
Audit Branch for Non-Compliance of Section 148 of the Companies Act,2013 for delay in filing Cost
Audit Report for which company has submitted its reply and awaiting instructions form Ministry of
Corporate Affairs.

60. CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE INSOLVENCY
AND BANKRUPTCY CODE, 2016 (IBC):

No corporate insolvency resolution process was initiated against the Company under the Insolvency
and Bankruptcy Code, 2016, during the year under review.

61. STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with regard to
the affairs of the Company in all respects.

62. DEVIATIONS, IF ANY OBSERVED-ON FUNDS RAISED THROUGH PUBLIC ISSUE,
PREFERENTIAL ISSUE ETC:

During the year under review, company has not raised any funds from public or through preferential
allotment.

63. ACKNOWLEDGEMENTS:

Your directors wish to place on record their appreciation of the contribution made by the employees at
all levels, to the continued growth and prosperity of your Company. Your directors also wish to place
on record their appreciation of business constituents, banks and other financial institutions and
shareholders of the Company for their continued support for the growth of the Company.

Date: 08.09.2025 Sd/- Sd/-

Place: Hyderabad S. Nagi Reddy S. Koni Reddy

Chairman & Managing Director Whole time Director & CFO

(DIN:01764665) (DIN:02829319)